 Announcement
May 22, 2024
Materialise Reports Strong Revenue Growth and Prepares for Annual Shareholders MeetingMaterialise NV, a leading provider of additive manufacturing software and advanced 3D printing solutions, has recently announced the date for its Annual General Shareholders Meeting. The meeting is scheduled to take place on June 4...
|
Business Update
May 22, 2024
Financial technology leader FIS has recently unveiled its latest version of the FIS Digital One Flex Mobile app, aimed at helping financial institutions adapt to changing customer expectations in the digital era. The upgraded application offers customers the flexibility to bank digitally via their preferred platform...
|
Business Update
May 22, 2024
Coya Therapeutics Completes Phase 2 Study of Low Dose Interleukin-2 in Alzheimer s Disease PatientsHouston-based biotechnology company, Coya Therapeutics, Inc. (NASDAQ: COYA), has recently announced the successful completion of a Phase 2 clinical trial for their experimental treatment, Low Dose Interleukin-2 (LD IL...
|
|
 Business Update
May 22, 2024
Evolv Technology, a security technology company known for its AI-based screening solutions, has joined forces with Lee Health, one of Florida s largest not-for-profit healthcare systems. Lee Health has implemented Evolv s state-of-the-art Evolv Express screening solution at the entrances of three emergency departmen...
 Business Update
May 22, 2024
OKLAHOMA CITY October 20, 2023 LSB Industries Inc. (NYSE: LXU) has entered into a landmark agreement, supplying up to 150,000 short tons per annum of low carbon ammonium nitrate solution (ANS) to Freeport Minerals Corporation (Freeport). This agreement solidifies LSB s positioning within the low-carbon product ...
|
|
Our most Popular Articles
|
Business Update
August 1, 2024
Dynatrace Marks Five Years of Innovation and Growth Post-IPOWALTHAM, Mass. In a remarkable milestone for the tech industry, Dynatrace (NYSE: DT), a leader in end-to-end observability and security, is celebrating the fifth anniversary of its initial public offering (IPO) on the New York Stock Exchange. Since its l...
|
Stocks on the Move
June 25, 2024
The Impact of Market Events on Naas Technology Inc: Analysis and Outlook The recent market events have raised concerns about Naas Technology Inc (NASDAQ: NAAS) and its position within the electric vehicle (EV) charging service sector in China. Among these events are the change in the ADS ratio, oil price fluctuation...
|
Clinical Study
July 24, 2024
Enhancing Treatment Options for Autoimmune and Hematologic Diseases: The Potential of NKX019 and NKX101 TherapiesThe field of immunotherapy has witnessed significant advancements in recent years, offering new hope for patients with autoimmune diseases and hematologic malignancies. One promising avenue of research in...
|
|
|
Company News
|
Business Update
May 22, 2024
Financial technology leader FIS has recently unveiled its latest version of the FIS Digital One Flex Mobile app, aimed at helping financial institutions adapt to changing customer expectations in the digital era. The upgraded application offers customers the flexibility to bank digitally via their preferred platform...
|
Business Update
May 22, 2024
Coya Therapeutics Completes Phase 2 Study of Low Dose Interleukin-2 in Alzheimer s Disease PatientsHouston-based biotechnology company, Coya Therapeutics, Inc. (NASDAQ: COYA), has recently announced the successful completion of a Phase 2 clinical trial for their experimental treatment, Low Dose Interleukin-2 (LD IL...
|
Business Update
May 22, 2024
In a constant endeavor to pioneer sustainable building solutions, Armstrong World Industries, Inc. (NYSE: AWI) has announced the launch of its groundbreaking product, Ultima Low Embodied Carbon (LEC) ceiling panels. As a frontrunner in ceiling and wall solutions, Armstrong continues to expand its portfolio, enabling...
|
|
|
Company News
 Partnership
May 22, 2024
|
Company News
 Product Service News
May 22, 2024
|
Company News
 Business Update
May 22, 2024
|
More Company News
|
Product Service News
May 22, 2024
|
Partnership
May 22, 2024
|
Product Service News
May 22, 2024
|
Contract
May 22, 2024
|
Business Update
May 22, 2024
|
Announcement
May 22, 2024
|
Licensing Agreement
May 22, 2024
|
Partnership
May 22, 2024
|
Partnership
May 22, 2024
|
Product Service News
Pioneering Cholesterol-Lowering Treatments NILEMDO and NUSTENDI Receive European Approval to Combat Hypercholesterolemia and Atherosclerosis
The European medical community has recently witnessed a significant breakthrough in the ongoing battle against cardiovascular disease. Esperion Therapeutics, Inc. has announced the European Commission's approval of their first-in-class oral cholesterol-lowering treatment, NILEMDO (bempedoic acid), and its combination with ezetimibe, NUSTENDI (bempedoic acid/ezetimibe fixed-dose combination). These novel treatments are designed to effectively lower low-density lipoprotein cholesterol (LDL-C) levels, address hypercholesterolemia, and significantly mitigate cardiovascular risk.
NILEMDO and NUSTENDI: Game Changers in Cholesterol Management
NILEMDO, also known as NEXLETOL in the U.S., stands out as a pioneering treatment in the cholesterol-lowering market due to its unique mechanism of action. Bempedoic acid, the active ingredient in NILEMDO, targets and inhibits ATP-citrate lyase (ACL), a key enzyme involved in the hepatic biosynthesis of cholesterol. This process ultimately results in reduced plasma levels of LDL-C, often termed bad cholesterol.
NUSTENDI (marketed as NEXLIZET in the U.S.) offers a powerful combination of bempedoic acid and ezetimibe, another established cholesterol-lowering agent that impedes the absorption of cholesterol in the intestines. Together, these agents provide a synergistic effect in managing LDL-C levels, offering a comprehensive solution for patients grappling with hypercholesterolemia who may not achieve their lipid goals with standard therapies alone.
Clinical trials and real-world evidence have heralded these therapies as safe and effective, fulfilling an urgent need for alternative treatments in the cardiovascular risk reduction arsenal. This label update approval by the European Commission underscores the pivotal role that NILEMDO and NUSTENDI will play in enhancing patient outcomes.
Linking Inflammation to Cardiovascular Events
Adding another layer to their robust cardiovascular research, Esperion presented an intriguing prespecified, exploratory analysis at the American Heart Association (AHA) Scientific Sessions 2023. This analysis, part of the CLEAR Outcomes study, examined the correlation between baseline inflammation levels and cardiovascular events among participants.
The study's findings highlighted a critical facet of cardiovascular risk management: individuals with higher baseline levels of inflammation were significantly more prone to experiencing major adverse cardiovascular events (MACE), cardiovascular death, and all-cause mortality compared to those with the lowest levels of inflammation. This compelling evidence accentuates the role of inflammation as a crucial predictor of cardiovascular risk, reinforcing the necessity for treatments that address both lipid levels and inflammatory pathways to optimize cardiovascular health.
The TRANSFORM Trial: Personalizing Heart Disease Care
In tandem with presenting the CLEAR Outcomes analysis, Esperion, along with its partners, announced the initiation of the transformative TRANSFORM Trial at the AHA 2023. This randomized control trial is set to revolutionize the evaluation and treatment of heart disease by focusing on the direct study of atherosclerosis'a leading cause of cardiovascular morbidity and mortality.
The TRANSFORM Trial aims to investigate personalized care strategies in treating heart disease, utilizing advanced diagnostic and therapeutic approaches to tailor interventions based on individual patient profiles. By evaluating the efficacy of personalized care in the management of atherosclerosis, the trial seeks to advance the evidence base and pave the way for more precise and effective cardiovascular therapies.
A Multi-faceted Approach to Cardiovascular Risk Reduction
The European approval of NILEMDO and NUSTENDI, alongside groundbreaking research such as the CLEAR Outcomes analysis and the TRANSFORM Trial, underscores Esperion's commitment to combating cardiovascular disease on multiple fronts. By integrating innovative treatments, predictive inflammation markers, and personalized care strategies, Esperion is poised to make substantial strides in reducing cardiovascular risk and improving patient outcomes worldwide.
These milestones reaffirm the imperative need for continued research and development in cardiovascular therapeutics. As medical science evolves, comprehensive strategies that address various facets of heart disease'cholesterol management, inflammation, and individualized care'will be paramount in achieving long-term health benefits for patients around the globe.
May 22, 2024
|
|
|
|
Related News
|
Announcement
|
Clinical Study
|
|
Stocks
|
|
Clinical Study
|
Clinical Study
|
Product Service News
|
|
|
|
Business News
|
|
Business Update
Evolv Technology, a security technology company known for its AI-based screening solutions, has joined forces with Lee Health, one of Florida s largest not-for-profit healthcare systems. Lee Health has implemented Evolv s state-of-the-art Evolv Express screening solution at the entrances of three emergency departmen...
|
|
Business Update
OKLAHOMA CITY October 20, 2023 LSB Industries Inc. (NYSE: LXU) has entered into a landmark agreement, supplying up to 150,000 short tons per annum of low carbon ammonium nitrate solution (ANS) to Freeport Minerals Corporation (Freeport). This agreement solidifies LSB s positioning within the low-carbon product ...
|
 Management Announcement
Crown Castle Shareholders Elect All Directors, Reflecting Support for Ongoing Value Creation Initiatives
In a recent announcement, Crown Castle, a leading provider of wireless infrastructure solutions, revealed that shareholders have elected all 12 of the company s director nominees. This outcome signifies a s...
|
 Announcement
By CSIMarket.com In an emblematic move that underscores its commitment to advancing the capabilities of specialty printing, Canon Solutions America has announced that Specialty Print Communications (SPC) will be the first U.S. installation site for the Canon ProStream 3160. This addition amplifies SPC s already ...
|
|
Announcement
Materialise Reports Strong Revenue Growth and Prepares for Annual Shareholders MeetingMaterialise NV, a leading provider of additive manufacturing software and advanced 3D printing solutions, has recently announced the date for its Annual General Shareholders Meeting. The meeting is scheduled to take place on June 4...
|
Our Most Popular Articles
|
 Business Update
Dynatrace Marks Five Years of Innovation and Growth Post-IPOWALTHAM, Mass. In a remarkable milestone for the tech industry, Dynatrace (NYSE: DT), a leader in end-to-end observability and security, is celebrating the fifth anniversary of its initial public offering (IPO) on the New York Stock Exchange. Since its l...
|
 Stocks on the Move
The Impact of Market Events on Naas Technology Inc: Analysis and Outlook The recent market events have raised concerns about Naas Technology Inc (NASDAQ: NAAS) and its position within the electric vehicle (EV) charging service sector in China. Among these events are the change in the ADS ratio, oil price fluctuation...
|
|
Clinical Study
Enhancing Treatment Options for Autoimmune and Hematologic Diseases: The Potential of NKX019 and NKX101 TherapiesThe field of immunotherapy has witnessed significant advancements in recent years, offering new hope for patients with autoimmune diseases and hematologic malignancies. One promising avenue of research in...
|
More News
|
 Business Update
Financial technology leader FIS has recently unveiled its latest version of the FIS Digital One Flex Mobile app, aimed at helping financial institutions adapt to changing customer expectations in the digital era. The upgraded application offers customers the flexibility to bank digitally via their preferred platform...
|
 Business Update
Coya Therapeutics Completes Phase 2 Study of Low Dose Interleukin-2 in Alzheimer s Disease PatientsHouston-based biotechnology company, Coya Therapeutics, Inc. (NASDAQ: COYA), has recently announced the successful completion of a Phase 2 clinical trial for their experimental treatment, Low Dose Interleukin-2 (LD IL...
|
 Business Update
In a constant endeavor to pioneer sustainable building solutions, Armstrong World Industries, Inc. (NYSE: AWI) has announced the launch of its groundbreaking product, Ultima Low Embodied Carbon (LEC) ceiling panels. As a frontrunner in ceiling and wall solutions, Armstrong continues to expand its portfolio, enabling...
|
 Partnership
Neo-Concept International and Reiss Limited Forge Strategic Partnership for New Co-Branded Collection May 22, 2024, HONG KONG - Neo-Concept International Group Holdings Limited (Nasdaq: NCI) has recently announced a significant collaboration that marks a pivotal move in their business strategy. The company, a domi...
|
 Product Service News
In the era of digital transformation, organizations are increasingly relying on Application Programming Interfaces (APIs) to enable seamless connectivity and data exchange between different systems. However, concerns over API security have soared in recent years, given the rising number of cyber threats targeting th...
|
 Business Update
VBI Vaccines Inc., a leading biopharmaceutical company dedicated to revolutionizing disease prevention and treatment through immunology, recently announced the acceptance of new interim tumor response data from their Phase 2b study of VBI-1901 for poster presentation at the 2024 American Society of Clinical Oncology...
|
|
Product Service News
In a groundbreaking development, the Hospital Santa Maria della Pietà , located in Nola in the Metropolitan City of Naples, has launched Southern Italy s first-ever robotic cardiac heart program. This state-of-the-art technology marks a significant milestone in the region s medical history, promising advanced and pr...
|
 Partnership
iPower Inc. Enhances SuperSuite Platform Capabilities through Strategic Partnership with Western PostRANCHO CUCAMONGA, Calif., May 22, 2024 - iPower Inc. (Nasdaq: IPW), a prominent tech and data-driven online retailer, has recently announced a strategic partnership with Western Post (US) LLC. This collaboration aims...
|
 Product Service News
Redesigned Grom Social App Debuting This Summer to Feature Custom Avatars Offering Kids Tips on Responsible Social Media Behavior Utilizing Grom Educationals Digital Citizenship License (DCL) CourseIn today’s technology-driven society, the importance of teaching younger generations responsible social media behavio...
|
 Contract
San Diego, CA, May 22, 2024 - In a significant move that further solidifies its presence in the energy storage and battery safety sectors, KULR Technology Group, Inc. (NYSE American: KULR), a global leader renowned for safe and high-performance energy storage solutions, has secured a pivotal engineering contract wit...
|
 Business Update
Pitney Bowes Implements Leadership Transition and New Initiatives to Drive Value CreationSTAMFORD, Conn. - Pitney Bowes Inc. (NYSE: PBI), a leading global shipping and mailing company, has announced a leadership transition along with new initiatives aimed at accelerating value creation. The company has appointed Lan...
|
 Announcement
SEALSQ USA Ltd Incorporated in Phoenix to Strengthen Global OSAT Network for Enhanced Localized Production and Support Geneva, Switzerland, May 22, 2024 SEALSQ, a leading semiconductor technology company, has recently announced the incorporation of SEALSQ USA Ltd in Phoenix, Arizona, as part of its strategy to stren...
|
 Licensing Agreement
In a series of transformative agreements, MaxCyte, a pioneering force in cell engineering and electroporation technology, has inked strategic platform licenses with three distinguished biotech companies: Legend Biotech, Wugen, and Imugene. These alliances underscore MaxCyte s pivotal role in advancing cell therapy innovations and scaling clinical and commercial manufacturing capacities. Legend Biotech s Strategic Leap with MaxCyte Legend Biotech, a global frontrunner in cell therapy discovery and development, has secured a license to utilize MaxCyte s Flow Electroporation® technology and ExPERT™ platform. This collaboration seeks to bolster Legend Biotech’s non-viral engineered pipeline, which spans various cell types including T cells, Gamma-Delta T cells, and Natural Killer (NK) cells. MaxCyte s cutting-edge technology will significantly enhance Legend Biotech s capabilities in creating innovative cell-based therapies. This agreement promises to expedite the treatment development process, potentially bringing life-saving therapies to patients more efficiently.
|
 Partnership
Montreal, Canada October 15, 2023 Milestone Pharmaceuticals, a biopharmaceutical company dedicated to the development and commercialization of innovative cardiovascular therapies, is excited to announce a new partnership with Arrhythmia Alliance to spearhead efforts aimed at increasing awareness around Supravent...
|
 Partnership
Investment in Clear Waters: A New Chapter in Sino-International CollaborationIn a significant stride toward enhancing environmental infrastructure, CDT Environmental Technology Investment Holdings Limited (CDT) has announced a strategic partnership with a subsidiary of a Fortune 500 company to jointly bid for a mon...
|
 Product Service News
Pioneering Cholesterol-Lowering Treatments NILEMDO and NUSTENDI Receive European Approval to Combat Hypercholesterolemia and Atherosclerosis
The European medical community has recently witnessed a significant breakthrough in the ongoing battle against cardiovascular disease. Esperion Therapeutics, Inc. has announced the European Commission's approval of their first-in-class oral cholesterol-lowering treatment, NILEMDO (bempedoic acid), and its combination with ezetimibe, NUSTENDI (bempedoic acid/ezetimibe fixed-dose combination). These novel treatments are designed to effectively lower low-density lipoprotein cholesterol (LDL-C) levels, address hypercholesterolemia, and significantly mitigate cardiovascular risk.
NILEMDO and NUSTENDI: Game Changers in Cholesterol Management
NILEMDO, also known as NEXLETOL in the U.S., stands out as a pioneering treatment in the cholesterol-lowering market due to its unique mechanism of action. Bempedoic acid, the active ingredient in NILEMDO, targets and inhibits ATP-citrate lyase (ACL), a key enzyme involved in the hepatic biosynthesis of cholesterol. This process ultimately results in reduced plasma levels of LDL-C, often termed bad cholesterol.
NUSTENDI (marketed as NEXLIZET in the U.S.) offers a powerful combination of bempedoic acid and ezetimibe, another established cholesterol-lowering agent that impedes the absorption of cholesterol in the intestines. Together, these agents provide a synergistic effect in managing LDL-C levels, offering a comprehensive solution for patients grappling with hypercholesterolemia who may not achieve their lipid goals with standard therapies alone.
Clinical trials and real-world evidence have heralded these therapies as safe and effective, fulfilling an urgent need for alternative treatments in the cardiovascular risk reduction arsenal. This label update approval by the European Commission underscores the pivotal role that NILEMDO and NUSTENDI will play in enhancing patient outcomes.
Linking Inflammation to Cardiovascular Events
Adding another layer to their robust cardiovascular research, Esperion presented an intriguing prespecified, exploratory analysis at the American Heart Association (AHA) Scientific Sessions 2023. This analysis, part of the CLEAR Outcomes study, examined the correlation between baseline inflammation levels and cardiovascular events among participants.
The study's findings highlighted a critical facet of cardiovascular risk management: individuals with higher baseline levels of inflammation were significantly more prone to experiencing major adverse cardiovascular events (MACE), cardiovascular death, and all-cause mortality compared to those with the lowest levels of inflammation. This compelling evidence accentuates the role of inflammation as a crucial predictor of cardiovascular risk, reinforcing the necessity for treatments that address both lipid levels and inflammatory pathways to optimize cardiovascular health.
The TRANSFORM Trial: Personalizing Heart Disease Care
In tandem with presenting the CLEAR Outcomes analysis, Esperion, along with its partners, announced the initiation of the transformative TRANSFORM Trial at the AHA 2023. This randomized control trial is set to revolutionize the evaluation and treatment of heart disease by focusing on the direct study of atherosclerosis'a leading cause of cardiovascular morbidity and mortality.
The TRANSFORM Trial aims to investigate personalized care strategies in treating heart disease, utilizing advanced diagnostic and therapeutic approaches to tailor interventions based on individual patient profiles. By evaluating the efficacy of personalized care in the management of atherosclerosis, the trial seeks to advance the evidence base and pave the way for more precise and effective cardiovascular therapies.
A Multi-faceted Approach to Cardiovascular Risk Reduction
The European approval of NILEMDO and NUSTENDI, alongside groundbreaking research such as the CLEAR Outcomes analysis and the TRANSFORM Trial, underscores Esperion's commitment to combating cardiovascular disease on multiple fronts. By integrating innovative treatments, predictive inflammation markers, and personalized care strategies, Esperion is poised to make substantial strides in reducing cardiovascular risk and improving patient outcomes worldwide.
These milestones reaffirm the imperative need for continued research and development in cardiovascular therapeutics. As medical science evolves, comprehensive strategies that address various facets of heart disease'cholesterol management, inflammation, and individualized care'will be paramount in achieving long-term health benefits for patients around the globe.
Pioneering Cholesterol-Lowering Treatments NILEMDO and NUSTENDI Receive European Approval to Combat Hypercholesterolemia and AtherosclerosisThe European medical community has recently witnessed a significant breakthrough in the ongoing battle against cardiovascular disease. Esperion Therapeutics, Inc. has announced...
|
|
|
|
|
